Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Eltrombopag Following Chemotherapy and G-CSF+/- Plerixafor for Mobilization and Collection of Hematopoietic Progenitor Cells (HPC) in Lymphoma and Myeloma Patients

Krishna Joshi, MD, Appalanaidu Sasapu, MD, Muthu Veeraputhiran, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Michele H Cottler-Fox, MD

Blood (2019) 134 (Supplement_1): 5638.

https://doi.org/10.1182/blood-2019-124629

Published: 2019

Journal Articles

Three Cases of Patients with Complement Regulatory Factor Genetic Mutations and Acquired Thrombotic Thrombocytopenic Purpura (TTP)

Shebli Atrash, MD, David Kent McKelvey, MD, Appalanaidu Sasapu, MD MS, Muthu Veeraputhiran, MD MPH, Soumya Pandey, MD, Michele H. Cottler-Fox, MD, Pooja Motwani, MD

Blood (2016) 128 (22): 1362.

https://doi.org/10.1182/blood.V128.22.1362.1362

Published: 2016

Journal Articles

JQ1, a Potential Therapeutic Molecule for Myeloid Leukemia with PTEN Deficiency

Nicholas J Baltz, Natalia C Colorado, MD, Yan Yan, MD, Shelly Lensing, MS, Delli Robinson, BA, Michele H. Cottler-Fox, MD, Jason E Farrar, MD, Peter Dean Emanuel, MD, Y. Lucy Liu, MD PhD

Blood (2016) 128 (22): 5899.

https://doi.org/10.1182/blood.V128.22.5899.5899

Published: 2016

Journal Articles

Validation of a Predictive Formula for Collection of Hematopoietic Progenitor Cells (HPC) By Leukapheresis at 2 Institutions Using 4 Different Machine Protocols

Eric R Rosenbaum, MD MPH, Patrick Wuchter, MD, Michael Hundemer, MD, Petra Pavel, MD, Mathias Witzens-Harig, MD, Hartmut Goldschmidt, MD, Bart Barlogie, MD PhD, Anthony Ho, MD, Michele H. Cottler-Fox, MD

Blood (2014) 124 (21): 2458.

https://doi.org/10.1182/blood.V124.21.2458.2458

Published: 2014

Journal Articles

Expanded Natural Killer (NK) Cells for Immunotherapy: Fresh and Made to Order

Susann Szmania, Natalia Lapteva, PhD, Tarun K. Garg, PhD, Joshuah D Lingo, Amy D Greenway, Amberly Bost, Katie Stone, Junaid Khan, Emily Woods, Bijay Nair, MD, Dario Campana, MD, PhD, Joshua Epstein, DSc, Malcolm K. Brenner, MD, PhD, Adrian P. Gee, PhD, Michele H. Cottler-Fox, MD, Bart Barlogie, MD, PhD, Cliona M. Rooney, PhD, Frits van Rhee, MD, PhD

Blood (2012) 120 (21): 1912.

https://doi.org/10.1182/blood.V120.21.1912.1912

Published: 2012

Journal Articles

Chemotherapy Does Not Enhance CD34+ Cell Collection When Added to Growth Factor and Plerixafor in Patients Who Are Poor Mobilizers

Eric R Rosenbaum, MD, MPH, Mayumi Nakagawa, MD, PhD, Gina Pesek, MD, John W Theus, MD, Bart Barlogie, MD, PhD, Michele H. Cottler-Fox, MD

Blood (2011) 118 (21): 4388.

https://doi.org/10.1182/blood.V118.21.4388.4388

Published: 2011

Journal Articles

The Immature Reticulocyte Fraction Predicts Marrow Recovery and Can Obviate the Need for Bone Marrow Examination in Persistently Neutropenic Cancer Patients

Sajjad Haider, MD, Lakshmikanth Katragadda, MD, Jameel Muzaffar, MD, Monica Grazziutti, MD, Muhammad R Akbar, MD, Michele H. Cottler-Fox, MD, Bart Barlogie, MD, Ph.D, Elias J. Anaissie, MD

Blood (2011) 118 (21): 4526.

https://doi.org/10.1182/blood.V118.21.4526.4526

Published: 2011

Journal Articles

Aldehyde Dehydrogenase (ALDH) Vs CD34 for Predicting Engraftment After Autologous Hematopoietic Progenitor Cell (autoHPC) Transplant

Muthu Veeraputhiran, Lakshmikanth Katragadda, Bart Barlogie, MD, PhD, Michele H. Cottler-Fox, MD

Blood (2010) 116 (21): 4441.

https://doi.org/10.1182/blood.V116.21.4441.4441

Published: 2010

Journal Articles

A 15 Hour Dosing-Collection Interval for Plerixafor Is at Least as Effective as the Standard 10 Hour Interval.

Eric R Rosenbaum, MD, Mayumi Nakagawa, MD, PhD, Gina Pesek, MD, John Theus, MD, Bart Barlogie, MD, PhD, Michele H. Cottler-Fox, MD

Blood (2009) 114 (22): 2152.

https://doi.org/10.1182/blood.V114.22.2152.2152

Published: 2009

Journal Articles

Viability and Engraftment of Hematopoietic Progenitor Cells (HPC) After Long Term Cryopreservation: Effect of Diagnosis and % Dimethylsulfoxide (DMSO) Concentration.

Muthu Kumaran Veeraputhiran, MD, MPH, John Theus, MD, Gina Pesek, MD, Bart Barlogie, MD, PhD, Michele H. Cottler-Fox, MD

Blood (2009) 114 (22): 3161.

https://doi.org/10.1182/blood.V114.22.3161.3161

Published: 2009

Journal Articles

High CD34 Yield Not Impaired by Melphalan 10mg/m2 Test-Dosing for Pharmacogenomics in M-VTD-PACE as Induction Therapy in Total Therapy 4 (TT4) for Low-Risk and Total Therapy 5 (TT5) for High-Risk Newly Diagnosed Multiple Myeloma (MM).

Frits van Rhee, MD, PhD, Yazan Alsayed, MD, PhD, Michele H. Cottler-Fox, MD, Jeff Haessler, MD, Sarah Waheed, MD, Bijay Nair, MD, John Crowley, PhD, Elias Anaissie, MD, PhD, Bart Barlogie, MD, PhD

Blood (2009) 114 (22): 3411.

https://doi.org/10.1182/blood.V114.22.3411.3411

Published: 2009

NARROW

Eltrombopag Following Chemotherapy and G-CSF+/- Plerixafor for Mobilization and Collection of Hematopoietic Progenitor Cells (HPC) in Lymphoma and Myeloma Patients

Three Cases of Patients with Complement Regulatory Factor Genetic Mutations and Acquired Thrombotic Thrombocytopenic Purpura (TTP)

JQ1, a Potential Therapeutic Molecule for Myeloid Leukemia with PTEN Deficiency

Validation of a Predictive Formula for Collection of Hematopoietic Progenitor Cells (HPC) By Leukapheresis at 2 Institutions Using 4 Different Machine Protocols

Expanded Natural Killer (NK) Cells for Immunotherapy: Fresh and Made to Order

Chemotherapy Does Not Enhance CD34+ Cell Collection When Added to Growth Factor and Plerixafor in Patients Who Are Poor Mobilizers

The Immature Reticulocyte Fraction Predicts Marrow Recovery and Can Obviate the Need for Bone Marrow Examination in Persistently Neutropenic Cancer Patients

Aldehyde Dehydrogenase (ALDH) Vs CD34 for Predicting Engraftment After Autologous Hematopoietic Progenitor Cell (autoHPC) Transplant

A 15 Hour Dosing-Collection Interval for Plerixafor Is at Least as Effective as the Standard 10 Hour Interval.

Viability and Engraftment of Hematopoietic Progenitor Cells (HPC) After Long Term Cryopreservation: Effect of Diagnosis and % Dimethylsulfoxide (DMSO) Concentration.

High CD34 Yield Not Impaired by Melphalan 10mg/m2 Test-Dosing for Pharmacogenomics in M-VTD-PACE as Induction Therapy in Total Therapy 4 (TT4) for Low-Risk and Total Therapy 5 (TT5) for High-Risk Newly Diagnosed Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only